UNSPSC 51281808: Esorubicin

This classification denotes an anthracycline antibiotic with the molecular formula C27H29NO10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, RMC41L2WQ3 chemically known as 5,12-naphthacenedione, 10-((4-aminotetrahydro-6-methyl-2h-pyran-2-yl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (2s-(2.alpha,(8r*,10r*),4.beta.,6.beta))- but generally known as esorubicin, which bears US NIH Compound Identifier 44554.

UNSPSC 51281808 Esorubicin (Commodity) shows little relevant recent activity under this code. The two most recent state and local opportunities tagged to the code involve entirely different pharmaceutical products — an Illinois Department of Public Health piggyback pharmaceutical warehouse contract for Doxycycline Hyclate and Ciprofloxacin Hydrochloride, and a Seminole County, Florida procurement for Naloxone and Safe Drug Deactivation Systems. Neither solicitation involves esorubicin, a chemotherapy agent. The mismatch between the code's nominal scope and what is actually being procured suggests either a cataloging error in the opportunities themselves or that state and local agencies are not actively sourcing esorubicin through open competitive bidding at this time.

The Illinois Department of Public Health contract, awarded to Chartwell Rx LLC on August 28, 2026, for $2,999,999.11 over three years with renewal options, reflects typical state pharmaceutical procurement through cooperative purchasing consortia (MMCAP Infuse), but the products supplied are antibiotics, not chemotherapy agents. The Seminole County opportunity from June 2026, an IFB with response due July 26, 2023, focuses on public-health emergency response supplies. Without recent open solicitations specifically requesting esorubicin, activity under this Commodity code cannot be characterized by issuing-body mix, geographic spread, or representative current opportunities.